Estudios originales
Published on 15 de mayo de 2026 | http://doi.org/10.5867/medwave.2026.04.3219
Quality of reporting of systematic reviews with meta-analysis of diagnostic test accuracy of rapid antigen tests for SARS-CoV-2 according to PRISMA-DTA: A meta-epidemiological survey
Back to article
Characteristics of the included studies (n=38).
| Year | 2020 | 1 | 3% |
| 2021 | 8 | 21% | |
| 2022 | 17 | 45% | |
| 2023 | 9 | 24% | |
| 2024 | 3 | 8% | |
| Country | Asia (Iran, China, Taiwan, Turkey, Malaysia, Bangladesh, Indonesia, South Korea, Nepal) | 20 | 53% |
| Europe (Germany, the United Kingdom, Greece, Italy) | 15 | 39% | |
| America (USA) | 2 | 5% | |
| Africa (Tunisia) | 1 | 3% | |
| Number of included primary studies | <25 | 17 | 45% |
| 25-99 | 14 | 37% | |
| 100-199 | 6 | 16% | |
| >200 | 1 | 3% | |
| Population characteristics | Adult and pediatric | 19 | 50% |
| Adult | 6 | 16% | |
| Pediatric | 3 | 8% | |
| Not reported/unclear | 10 | 26% | |
| Sample size | <5,000 | 5 | 13% |
| 5,000-99,999 | 24 | 63% | |
| 100,000-199,999 | 7 | 18% | |
| ≥200,000 | 2 | 5% | |
| Summary sensitivity | <60% | 1 | 3% |
| 60%-69,9% | 14 | 37% | |
| 70%-79,9% | 16 | 42% | |
| 80%-89,9% | 5 | 13% | |
| ≥90% | 1 | 3% | |
| Not reported | 1 | 3% | |
| Summary specificity | <98% | 2 | 5% |
| ³98% | 34 | 90% | |
| Not reported | 2 | 5% | |